Table 2.
Characteristics of patients with minimal change nephrotic syndrome at sampling who underwent gene expression analysis
| Patient no. | Sex | Age at onset | Total follow-up perioda (months) | Frequent relapser | Biopsy | Sampling age at relapse | Relapse times at sampling (n) | Intervalsb (weeks) | PSL at relapse (mg/day) | PLS at remission (mg/day) | IS at relapse (mg/day) | IS at remission (mg/day) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | M | 8y4m | 121 | Yes | MC | 11y11m | 8 | 1 | 10 | 60 | MZV150 | MZV150 |
| 8 | M | 10y4m | 78 | Yes | MC | 13y8m | 5 | 2 | 0 | 0 | 0 | 0 |
| 9 | M | 2y5m | 154 | Yes | MC | 17y9m | 20 | 3 | 60 | 40 | MZV150 | MZV150 |
| 10 | F | 4y3m | 44 | No | ND | 6y2m | 2 | 26 | 0 | 0 | 0 | 0 |
| 11 | F | 4y10m | 130 | Yes | ND | 15y0m | 8 | 1 | 0 | 30 | 0 | 0 |
| 12 | F | 10y3m | 36 | Yes | ND | 14y0m | 4 | 13 | 0 | 20ADT | CyA50 | CyA50 |
| 13 | F | 4y7m | 37 | Yes | MC | 6y7m | 7 | 8 | 0 | 0 | CyA80 | CyA80 |
| Mean | 6y5m | 85.7 | 12y1m | 7.7 | 7.7 |
F, Female
aFollow-up period till June 2011
bIntervals of sampling between relapse and remission